Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
24.96
+0.38 (1.55%)
At close: May 30, 2025, 4:00 PM
25.00
+0.04 (0.16%)
After-hours: May 30, 2025, 7:53 PM EDT

Catalyst Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 7 professional analysts, the 12-month price target for Catalyst Pharmaceuticals stock ranges from a low of $29 to a high of $36. The average analyst price target of $32.29 forecasts a 29.37% increase in the stock price over the next year.

Price Target: $32.29 (+29.37%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $29 $32.29 $32 $36
Change +16.19% +29.37% +28.21% +44.23%
* Price targets were last updated on Mar 3, 2025.

Analyst Ratings

The average analyst rating for Catalyst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Dec '24Jan '25Feb '25Mar '25Apr '25May '25
Strong Buy 444444
Buy 334443
Hold 000000
Sell 000000
Strong Sell 000000
Total 778887

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Baird
Baird
Buy
Maintains
$28$32
Buy Maintains $28$32 +28.21% Mar 3, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$35
Strong Buy Reiterates $35 +40.22% Feb 28, 2025
Stephens & Co.
Stephens & Co.
Buy
Reiterates
$33
Buy Reiterates $33 +32.21% Feb 27, 2025
Baird
Baird
Buy
Initiates
$28
Buy Initiates $28 +12.18% Feb 4, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$30$35
Strong Buy Maintains $30$35 +40.22% Jan 10, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
572.23M
from 491.73M
Increased by 16.37%
Revenue Next Year
622.61M
from 572.23M
Increased by 8.80%
EPS This Year
1.49
from 1.31
Increased by 13.68%
EPS Next Year
1.73
from 1.49
Increased by 15.87%
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
119.07M140.83M214.20M398.20M491.73M572.23M622.61M697.07M
Revenue Growth
16.39%18.28%52.10%85.90%23.49%16.37%8.80%11.96%
EPS
0.710.370.750.631.311.491.731.91
EPS Growth
136.67%-47.89%102.70%-16.00%107.94%13.68%15.87%10.84%
Forward PE
-----16.7614.4713.05
No. Analysts
-----10108
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 594.7M 686.2M 819.8M
Avg 572.2M 622.6M 697.1M
Low 540.7M 547.0M 620.1M

Revenue Growth

Revenue Growth 20252026202720282029
High
20.9%
19.9%
31.7%
Avg
16.4%
8.8%
12.0%
Low
10.0%
-4.4%
-0.4%

EPS Forecast

EPS 20252026202720282029
High 1.58 2.32 2.39
Avg 1.49 1.73 1.91
Low 1.40 1.06 1.53

EPS Growth

EPS Growth 20252026202720282029
High
20.2%
55.8%
38.7%
Avg
13.7%
15.9%
10.8%
Low
7.0%
-28.9%
-11.4%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.